Biopharmaceutical News and Research

RSS

New benchmark: 1 kg of plasmid DNA manufactured

Kaneka Eurogentec sets new benchmark in plasmid DNA manufacturing with the production of 1 kg of plasmid DNA.

From Kaneka Eurogentec S.A 27 Aug 2024

Drug shows new promise in treating breast cancer with brain metastases or recurrent glioblastoma

A drug effective in treating breast cancer shows new promise in addressing breast cancer with brain metastases or recurrent glioblastoma, as reported by results of a prospective window-of-opportunity trial at the University of Texas Health Science Center at San Antonio (UT Health San Antonio).

8 Aug 2024

Researchers identify strategy to design safer opioids

Opioid medications offer people relief from debilitating pain, but these drugs come with dangers: the risk for addiction, miserable withdrawal symptoms and the potential for fatal overdose.

2 Aug 2024

Targeting 14 modifiable risk factors from childhood to old age could prevent or delay dementia

Addressing 14 modifiable risk factors, starting in childhood and continuing throughout life, could prevent or delay nearly half of dementia cases, even as people around the world live longer and the number of people with dementia is set to rise dramatically in all countries, according to the third Lancet Commission on dementia prevention, intervention, and care, which is being presented at the Alzheimer's Association International Conference (AAIC 2024).

1 Aug 2024

MD Anderson and collaborators initiate space project to explore T cell behavior in microgravity

The University of Texas MD Anderson Cancer Center and collaborators are initiating a research project that will send T cells to the International Space Station (ISS) to study the effects of prolonged microgravity on cell differentiation, activation, memory and exhaustion.

31 Jul 2024

MD Anderson and Summit Therapeutics partner to accelerate ivonescimab development

The University of Texas MD Anderson Cancer Center and Summit Therapeutics, Inc. today announced a strategic five-year collaboration agreement for the purpose of accelerating the development of ivonescimab.

25 Jul 2024

Waters new Rapid Screening-DSC enables up to 24x faster thermal stability testing at ultra-low sample volumes for antibody drugs

Waters Corporation announced today the global release of the TA Instruments™ Rapid Screening-Differential Scanning Calorimeter (TA Instruments RS-DSC), designed for biopharmaceutical developers. The TA Instruments RS-DSC is a high-throughput DSC for precise thermal stability testing of high-concentration biologic formulations specifically for antibody drugs and engineered proteins

From TA Instruments 24 Jul 2024

Metrion Biosciences appoints Dr Chris Mathes as Chief Commercial Officer

Metrion Biosciences Ltd (“Metrion”), the specialist preclinical contract research organization (CRO) and a leader in ion channel screening, today announced the appointment of Dr Chris Mathes, MBA, as Chief Commercial Officer (CCO). Chris will work alongside the Company’s expert leadership team to drive commercial strategy and lead global business development and marketing activities.

24 Jul 2024

Enterprise Therapeutics doses first person with cystic fibrosis in Phase 2 trial for novel therapy ETD001

Enterprise Therapeutics Ltd (Enterprise), a biopharmaceutical company dedicated to the discovery and development of novel therapies to improve the lives of those suffering from respiratory disease, today announced dosing of the first person with cystic fibrosis (pwCF) in its Phase 2a trial of ETD001.

24 Jul 2024

Lario Therapeutics awarded $6M Grant from The Michael J. Fox Foundation for Parkinson’s Research

Award supports preclinical research of Lario’s CaV2.3 calcium channel inhibitors as a novel disease-modifying approach for treatment of Parkinson's disease.

23 Jul 2024

Almirall's Ebglyss recommended by NICE for NHS atopic dermatitis patients

Almirall S.A., a global biopharmaceutical company dedicated to medical dermatology, announced today that the National Institute for Health and Care Excellence (NICE) has recommended Ebglyss (lebrikizumab) for use in moderate to severe Atopic Dermatitis in the NHS England.

13 Jul 2024

Click-like chemistry enables rapid development of LNPs for enhanced mRNA delivery

Imagine a scenario where a skilled hacker must upload critical software to update a central server and thwart a potentially lethal virus from wreaking havoc across a vast computer network.

10 Jul 2024

Agreement to explore Optimer vehicles for targeted delivery of siRNA

New collaboration will evaluate Aptamer’s fibrotic liver delivery vehicles with siRNA.

From Aptamer Group 9 Jul 2024

ELRIG UK and The Protein Society Partner to advance protein sciences in drug discovery

Partners to host joint conference on ‘Protein Sciences in Drug Discovery’ in Cambridge, UK from 18–19 November 2024.

From ELRIG (UK) Ltd. 26 Jun 2024

UT Health Science Center awarded $1.58M grant to study cancer disparities among Black women

A $1.58 million grant will support work by a health communication scholar at the University of Tennessee (UT) Health Science Center's College of Nursing and a medical oncologist at West Cancer Center and Research Institute (WCCRI) to identify sociocultural and structural factors that are root causes of cancer health disparities for Black women in the Mid-South.

20 Jun 2024

WEHI spinout aims to revolutionize the development of cancer drugs

Australia has cemented its role in becoming a major player in the next generation of medicines with the launch of Ternarx – a globally competitive biotechnology company dedicated to finding new treatments for hard-to-treat cancers.

20 Jun 2024

Gyros Protein Technologies introduces Gyrolab Generic Anti-AAV Kit to support gene therapy development

Ready-to-use kit enables detection of binding antibodies against AAV vectors without the need for serotype-specific assays.

From Gyros Protein Technologies AB 17 Jun 2024

Enterprise Therapeutics appoints Dr Renu Gupta as Chief Medical Officer and Dr Janet Hammond as Non-Executive Director

Appointments bring additional respiratory and late clinical-stage drug development experience as Company commences Phase 2a clinical trial of its lead asset.

From Enterprise Therapeutics Ltd 17 Jun 2024

Enterprise Therapeutics publishes preclinical profile of ETD001, a novel inhaled ENaC blocker

Enterprise Therapeutics Ltd (Enterprise), a biopharmaceutical company dedicated to the discovery and development of novel therapies to improve the lives of people with respiratory diseases, today announced the publication of a peer reviewed study in the Journal of Cystic Fibrosis1.

12 Jun 2024

InDevR and Sino Biological team up to deliver multiplexed analytical solutions for mRNA vaccine and cell & gene therapy

InDevR, Inc., a leader in analytical solutions for vaccine in-process and quality control testing, and Sino Biological, Inc., a biotechnology company listed on the Shenzhen stock exchange subsidiary ChiNext specializing in biological research reagents and related technical contract research services, today announced a new partnership to speed development of multiplexed assays for a broad range of vaccine, mRNA therapies and cell and gene therapy applications.

From Sino Biological Inc. 7 Jun 2024